Pancreatic cancer: current options for diagnosis, staging and therapeutic management

Background: Pancreatic cancer is characterized by frequently delayed diagnosis and aggressive tumor growth which hampers most of the current treatment modalities. This review aims to summarize the available evidence about the diagnostic and therapeutic aspects of resectable and non-resectable pancre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Hartwig, Werner (VerfasserIn) , Büchler, Markus W. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2014
In: Gastrointestinal tumors
Year: 2013, Jahrgang: 1, Heft: 1, Pages: 41-52
ISSN:2296-3766
DOI:10.1159/000354992
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000354992
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/354992
Volltext
Verfasserangaben:Werner Hartwig, Markus W. Büchler

MARC

LEADER 00000caa a2200000 c 4500
001 1744425604
003 DE-627
005 20230428033021.0
007 cr uuu---uuuuu
008 210112r20142013xx |||||o 00| ||eng c
024 7 |a 10.1159/000354992  |2 doi 
035 |a (DE-627)1744425604 
035 |a (DE-599)KXP1744425604 
035 |a (OCoLC)1341385146 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hartwig, Werner  |d 1970-  |e VerfasserIn  |0 (DE-588)115574646  |0 (DE-627)077338219  |0 (DE-576)289957494  |4 aut 
245 1 0 |a Pancreatic cancer  |b current options for diagnosis, staging and therapeutic management  |c Werner Hartwig, Markus W. Büchler 
264 1 |c 2014 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Published online: September 12, 2013 
500 |a Gesehen am 12.01.2021 
520 |a Background: Pancreatic cancer is characterized by frequently delayed diagnosis and aggressive tumor growth which hampers most of the current treatment modalities. This review aims to summarize the available evidence about the diagnostic and therapeutic aspects of resectable and non-resectable pancreatic cancer therapy. Summary: Embedded in the concept of multimodal therapy, surgery plays the central role in the treatment of pancreatic cancer. With advantageous tumor characteristics and complete tumor resection as the most relevant positive prognostic factors, the detection of premalignant or early invasive lesions combined with safe and oncologic adequate surgery is the major therapeutic aim. Most pancreatic adenocarcinomas are locally advanced or metastatic when diagnosed and need to be treated by the combination of surgery and (radio)chemotherapy or by palliative chemotherapy. Key Message An interdisciplinary, multimodal approach to therapy is critical for improving the outcomes of patients with pancreatic cancer. Practical Implications Cross-sectional imaging techniques (such as contrast-enhanced multidetector computed tomography) are useful for assessing tumor resectability. For localized, non-metastatic, resectable tumors, the necessity of preoperative biopsies remains controversial. Important prognostic parameters are tumor size, invasion of surrounding tissue, lymph node metastasis and distant metastasis. Various classification systems based on the TNM system have been used for tumor staging and prognosis. The presence of distant metastases is regarded as non-resectable disease, requiring chemotherapy as first treatment. The definition of borderline resectable tumors is still under debate, although a recent definition has been provided by an expert consensus statement. Standard lymphadenectomy is the recommended procedure in pancreatoduodenectomy, based upon the guidelines of the International Study Group of Pancreatic Surgery (ISGPS). Adjuvant chemotherapy is applied in generally all cases of pancreatic ductal adenocarcinoma following macroscopic complete tumor resection. The benefits of adjuvant chemoradiotherapy or immunochemoradiotherapy, or neoadjuvant therapy, however, remain a matter of controversy. For palliative treatment gemcitabine monotherapy is widely used; the FOLFIRINOX protocol provides an alternative for a minority of patients. 
534 |c 2013 
700 1 |a Büchler, Markus W.  |d 1955-  |e VerfasserIn  |0 (DE-588)120893339  |0 (DE-627)080952526  |0 (DE-576)292434146  |4 aut 
773 0 8 |i Enthalten in  |t Gastrointestinal tumors  |d [Fayetteville, Ga.] : Maximum Academic Press, 2013  |g 1(2014), 1, Seite 41-52  |h Online-Ressource  |w (DE-627)769570194  |w (DE-600)2735769-7  |w (DE-576)394189647  |x 2296-3766  |7 nnas  |a Pancreatic cancer current options for diagnosis, staging and therapeutic management 
773 1 8 |g volume:1  |g year:2014  |g number:1  |g pages:41-52  |g extent:12  |a Pancreatic cancer current options for diagnosis, staging and therapeutic management 
856 4 0 |u https://doi.org/10.1159/000354992  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.karger.com/Article/FullText/354992  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210112 
993 |a Article 
994 |a 2014 
998 |g 120893339  |a Büchler, Markus W.  |m 120893339:Büchler, Markus W.  |d 910000  |d 910200  |e 910000PB120893339  |e 910200PB120893339  |k 0/910000/  |k 1/910000/910200/  |p 2  |y j 
998 |g 115574646  |a Hartwig, Werner  |m 115574646:Hartwig, Werner  |d 50000  |e 50000PH115574646  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1744425604  |e 3834549398 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"given":"Werner","family":"Hartwig","display":"Hartwig, Werner","role":"aut"},{"family":"Büchler","given":"Markus W.","role":"aut","display":"Büchler, Markus W."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1744425604"],"doi":["10.1159/000354992"]},"note":["Published online: September 12, 2013","Gesehen am 12.01.2021"],"physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Werner Hartwig, Markus W. Büchler"]},"origin":[{"dateIssuedDisp":"2014","dateIssuedKey":"2014"}],"relHost":[{"recId":"769570194","origin":[{"publisherPlace":"[Fayetteville, Ga.] ; Basel","publisher":"Maximum Academic Press ; Karger","dateIssuedDisp":"September 2013-"}],"note":["Gesehen am 14.08.25"],"part":{"issue":"1","year":"2014","text":"1(2014), 1, Seite 41-52","pages":"41-52","volume":"1","extent":"12"},"titleAlt":[{"title":"GI Tumors"},{"title":"Gastrointest Tumors"}],"title":[{"title_sort":"Gastrointestinal tumors","title":"Gastrointestinal tumors"}],"pubHistory":["Vol. 1, no. 1 (2014)-"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"Pancreatic cancer current options for diagnosis, staging and therapeutic managementGastrointestinal tumors","id":{"eki":["769570194"],"zdb":["2735769-7"],"issn":["2296-3766"],"doi":["10.1159/issn.2296-3774"]},"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"recId":"1744425604","title":[{"title":"Pancreatic cancer","title_sort":"Pancreatic cancer","subtitle":"current options for diagnosis, staging and therapeutic management"}]} 
SRT |a HARTWIGWERPANCREATIC2014